Multiple Myeloma

News Multiple Myeloma

• EMA recommends approval of pomalidomide for the treatment of multiple myeloma

  The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Pomalidomide Celgene (pomalidomide) to treat patients with multiple myeloma. Multiple myeloma is a rare and incurable cancer of the bone marrow that primarily affects old more

• NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer

  NOXXON Pharma announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer® NOX-A12. CXCL12 signaling has been shown to play an important role in the pat more

• Possible new therapy for the treatment of a common blood cancer

  Research from Karolinska Institutet in Sweden shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common forms of blood cancer and is generally incurable. “Recently developed drugs, like bort more

Publications Multiple Myeloma

• Multiplex ligation‐dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma

  Multiple myeloma (MM) is a genetically heterogeneous disease with diverse clinical outcomes. Interphase fluorescence in situ hybridization (i‐FISH) is the most commonly used approach to detect recurrent cytogenetic abnormalities in this malignancy. We aimed to assess the performance of multiplex l more

• Bortezomib and heart failure: case‐report and review of the French Pharmacovigilance database

  Summary Bortezomib is a proteasome inhibitor commonly indicated for the treatment of multiple myeloma and non Hodgkin lymphoma. Cardiac adverse drug reactions of this drug are not clearly established. We report case where direct involvement of bortezomib in the occurrence of heart failure is str more

• FGF Receptors: Cancer Biology and Therapeutics

  Abstract Fibroblast growth factors (FGFs) are involved in a variety of cellular processes, such as stemness, proliferation, anti‐apoptosis, drug resistance, and angiogenesis. Here, FGF signaling network, cancer genetics/genomics of FGF receptors (FGFRs), and FGFR‐targeted therapeutics will be re more

Market studies Multiple Myeloma

• Multiple Myeloma (Kahler's Disease) – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Multiple Myeloma (Kahler's Disease) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Multiple Myeloma (Kahler's Disease), complete with latest updat more

• A Tale of Two Multiple Myeloma Therapies - The Race for Accelerated Approval

  Introduction Multiple myeloma patients with relapsed and refractory disease are underserved by current pharmaceutical offerings. Two drugs, Onyx’s proteasome inhibitor carfilzomib and Celgene’s immunomodulatory drug pomalidomide, are currently being evaluated for accelerated approval from the FDA more

• Refractory Multiple Myeloma – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Refractory Multiple Myeloma - Pipeline Review, H2 2012', provides an overview of the Refractory Multiple Myeloma therapeutic pipeline. This report provides information on the therapeutic development for Refractory Multiple Myeloma, complete with latest update more

Websites Multiple Myeloma